Preclinical Ty21a-Based Cancer Vaccine Development

Q: Why use Ty21a as a 'Seed Vaccine' in combination with Checkpoint Inhibitors?

Ty21a acts as a 'seed' to induce an initial inflammatory response and prime antigen-specific T cells, transforming 'cold' tumors into responsive targets for subsequent Checkpoint Inhibitor therapy.

Q: Does pre-existing immunity to Salmonella interfere with the Ty21a vaccine?

Preclinical data suggest that even with pre-existing immunity, the vector remain effective due to its rapid entry into APCs and colonization of tumor tissues before neutralization.

Harnessing the power of a clinically-proven bacterial vector for next-generation oncology. Creative Biolabs offers specialized preclinical development solutions for Salmonella Typhi Ty21a-vectored cancer vaccines.

Our platform transforms the stable Ty21a chassis into a potent multivalent antigen delivery system. By combining natural CpG-mediated immune stimulation with the ability to penetrate solid tumors, we provide a "seed" vaccine strategy that primes the immune system for sustained antitumor responses.

Request Preclinical Project Design

Ty21a: A Proven Safety Record Meets Modern Oncology

Ty21a is an attenuated strain of Salmonella Typhi that has been used globally for over 30 years. Its unique biological properties make it a premier candidate for cancer immunotherapy development:

▶ Unrivaled Safety & Stability: With a decades-long record of oral administration, Ty21a offers a genetically stable and exceptionally safe vector chassis for industrial-scale development.
▶ Natural Adjuvant Effect: Ty21a inherently triggers the innate immune system via CpG stimulation of TLR9, enhancing the immunogenicity of delivered tumor antigens without external adjuvants.
▶ Bactofection & APC Targeting: The ability of Ty21a to actively enter and deliver genetic payloads directly to Antigen Presenting Cells (APCs) ensures efficient MHC class I and II presentation.

Comprehensive Preclinical Development Solutions

We provide end-to-end support to engineer Ty21a into a high-performance therapeutic vehicle:

Custom Ty21a Vector Engineering

Strategic integration of single or multivalent TAAs (Tumor-Associated Antigens) using stable genomic insertion or high-copy plasmid systems optimized for bacterial expression.

Multivalent Delivery Optimization

Simultaneous delivery of diverse payloads, including HPV proteins, toxins, or personalized neoantigens, leveraging Ty21a’s large genomic capacity for synergistic effects.

In Vitro Mechanistic Validation

Quantitative assessment of bactofection efficiency, APC maturation, and antigen presentation (MHC I/II) to ensure lead candidates activate the desired immune pathways.

In Vivo Efficacy & Safety Profiling

Evaluating tumor growth inhibition, longitudinal immune response tracking, and biodistribution in syngeneic models to establish a robust preclinical data package.

Featured Preclinical Focus Areas

Our expertise spans various applications of Ty21a technology to meet diverse research and development objectives:

Viral-Associated Cancers

Leveraging Ty21a to deliver high-risk viral antigens (e.g., HPV-E6/E7) for therapeutic vaccination against cervical, head, and neck malignancies.

Explore HPV Solutions →

Cold-to-Hot TME Transition

Utilizing Ty21a’s natural pro-inflammatory signaling to recruit TILs and reverse the immunosuppressive microenvironment of "cold" tumors.

Learn About TME Mapping →

Neoantigen Delivery Platform

Customizing the Ty21a chassis to carry multiple patient-specific neoantigens, ensuring high genetic stability and efficient APC presentation.

View Custom Engineering →

Oral Immunotherapy Prototypes

Developing stabilized oral vaccine formulations that exploit Ty21a’s natural route of entry to activate mucosal and systemic immunity.

Get Formulation Details →

Agile Preclinical Ty21a Vaccine Development Pipeline

Our systematic workflow is designed to accelerate the transition from concept to candidate selection:

Step 1: Vector Design & Genomic Stability Assessment

Activities: We perform bioinformatic optimization of the target antigen sequence and select the ideal integration site within the Ty21a genome. Longitudinal stability assays are conducted to ensure the payload remains genetically locked over multiple generations of bacterial replication.

Outcome: A verified, genetically stable Ty21a-antigen construct.

Step 2: Multivalent Expression & Payload Optimization

Activities: Engineering multivalent systems to deliver multiple TAAs or combination payloads. We optimize bacterial promoters and secretion signals to maximize antigen loading within the bacterial cytoplasm or periplasm for efficient delivery upon entry into APCs.

Outcome: Optimized multivalent Ty21a lead constructs with confirmed expression profiles.

Step 3: In Vitro Bactofection & APC Characterization

Activities: Using primary human or murine DCs and macrophages, we quantify the efficiency of Ty21a-mediated gene/protein delivery. We measure APC maturation markers (CD80/86) and cytokine signatures (IL-12, IFN-γ) to validate the natural adjuvant effect.

Outcome: Functional proof-of-concept data for APC targeting and activation.

Step 4: In Vivo Immune Priming & Antitumor Analysis

Activities: Testing in syngeneic tumor models (e.g., CT26, B16-F10). We track the expansion of antigen-specific T cells via tetramer staining and ELISpot, while monitoring tumor volume and survival rates to quantify therapeutic potency.

Outcome: Quantitative efficacy data supporting lead candidate selection.

Step 5: Combination Synergy & "Seed" Strategy Validation

Activities: Evaluating the Ty21a vaccine as a "seed" to prime the immune system followed by Checkpoint Inhibitors (ICIs). We analyze the transformation of the TME and the ability of the combination to maintain long-term antitumor memory.

Outcome: A comprehensive synergy report optimized for downstream development decisions.

Request Detailed Timeline

Specialized Bacterial Vector Engineering Platforms

Our Ty21a solutions are powered by proprietary systems tailored for the unique complexities of live bacterial therapeutics:

Ty-Genomic Stable Engine: A sophisticated recombineering system that allows for scarless, site-specific insertion of payloads into the Ty21a chromosome. This ensures maximal stability without the need for antibiotic selection, ideal for industrial-scale development.

High-fidelity genomic mapping of the Ty21a chassis
Stability validation across 100+ generations of replication
Minimal metabolic burden on the bacterial host for high-yield production

Multivalency Payload Suite: Advanced engineering platform designed to load multiple tumor antigens or immune modulators into a single Ty21a vehicle. This platform enables the targeting of tumor heterogeneity and prevents immune escape.

Simultaneous delivery of up to 5 distinct TAAs
Customizable secretion systems for extracellular or cytosolic delivery
Co-expression of cytokines to further modulate the TME

Immuno-Sentinel Analytical Platform: A comprehensive suite of immunological assays designed specifically to monitor the unique innate-adaptive interaction triggered by Ty21a vectors, including TLR9 activation tracking and longitudinal memory T-cell profiling.

High-sensitivity CpG/TLR9 activation assays
Spatial analysis of Ty21a penetration into solid tumors
Multiplex profiling of the TME "cold-to-hot" transition

Ty-Genomic Engine

Multivalency Suite

Immuno-Sentinel

Scientific Insight: Ty21a as a "Seed" for Potent Immunotherapy

Ty21a: Multivalent Antigen Delivery & Combination Therapy (Renteria-Flores et al., 2024)

Discovery: A recent review in Vaccines highlights the immense potential of Salmonella Typhi Ty21a as a cancer vaccine platform. The study underscores its ability to deliver multiple antigens (e.g., HPV, Anthrax toxins) while providing a natural adjuvant effect through CpG stimulation.

Research Highlights:

Multivalent Strategy: Validates Ty21a as a highly versatile carrier for diverse TAAs, overcoming the limitations of single-antigen vaccines.
Seed Vaccine Strategy: Proposes the use of Ty21a to prime ("seed") the immune response, transforming non-immunogenic tumors into responsive targets for Checkpoint Inhibitors (ICIs).
Safety Benchmark: Reinforces Ty21a’s 30+ year safety record and genomic stability as the gold standard for industrial bacterial vaccine production.

Main mechanisms of bactofection-induced immune response against codified antigen using orally administered S. typhimurium.

Fig.1 Mechanism of bactofection by oral S. typhimurium for antigen-specific immune response.^1,2

Frequently Asked Questions

Q: How does Ty21a's safety compare to other live bacterial vectors like Listeria?

A: Ty21a has a vastly superior safety profile, with over 30 years of global use as a licensed oral vaccine. Its attenuation is genetically stable, and unlike some Listeria-based vectors, it does not pose a significant risk of systemic toxicity in preclinical models, making it a safer chassis for oncology applications.

Q: Can Ty21a deliver multiple antigens simultaneously to target tumor heterogeneity?

A: Yes. One of the primary advantages of our Ty21a platform is its multivalent capacity. We can engineer the vector to deliver up to 5 distinct tumor antigens or neoantigens, which is critical for preventing immune escape and addressing the polyclonal nature of solid tumors.

Q: What is "Bactofection" and how does Ty21a achieve it?

A: Bactofection is the process where bacteria deliver a genetic payload directly into host cells. Ty21a is naturally phagocytosed by APCs; once inside, it escapes the phagosome or lyses, releasing DNA or protein payloads into the cytosol, which leads to robust MHC class I cross-presentation and CD8+ T-cell activation.

Q: Why use Ty21a as a "Seed Vaccine" in combination with Checkpoint Inhibitors?

A: Many tumors are "cold" and non-responsive to ICIs because they lack T-cell infiltration. Ty21a acts as a "seed" to induce an initial inflammatory response and prime antigen-specific T cells. This "warms up" the TME, making subsequent ICI therapy significantly more effective.

Q: Does pre-existing immunity to Salmonella interfere with the Ty21a vaccine?

A: Preclinical data suggest that even in the presence of anti-Salmonella immunity, the vector remains effective. The ability of Ty21a to rapidly enter APCs and colonize tumor tissues allows it to deliver antigens before being neutralized, ensuring the induction of new antitumor responses.

Related Resources

References:
1. Renteria-Flores, Francisco Israel, Mariel García-Chagollán, and Luis Felipe Jave-Suárez. "Bactofection, Bacterial-Mediated Vaccination, and Cancer Therapy: Current Applications and Future Perspectives." Vaccines 12.9 (2024): 968.
2. Distributed under Open Access License CC BY 4.0, without modification.